Welcome to our dedicated page for Atyr Pharma SEC filings (Ticker: ATYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
aTyr Pharma, Inc. filings document a clinical-stage biotechnology issuer focused on tRNA synthetase-derived medicines and the efzofitimod program for interstitial lung disease. Form 8-K reports furnish quarterly and annual results, corporate updates, and clinical-study disclosures, including EFZO-FIT results in pulmonary sarcoidosis.
Proxy materials describe board elections, stockholder meeting proposals, executive compensation, equity awards, and governance practices. The filing record also reflects capital-structure and stock-based compensation disclosures relevant to a development-stage biotechnology company funding research, clinical trials, and manufacturing activities for its lead program.
aTyr Pharma, Inc. reported first quarter 2026 results and outlined next steps for its lead drug efzofitimod in interstitial lung disease. The company plans to submit an IND in June 2026 for a global Phase 3 pulmonary sarcoidosis study and is on track to complete enrollment in its Phase 2 EFZO-CONNECT SSc-ILD trial in the first half of 2026.
aTyr ended the quarter with $68.3 million in cash, cash equivalents, restricted cash and investments. Net loss attributable to aTyr was $10.8 million, compared with $14.9 million a year earlier, with net loss per share of $0.11 versus $0.17 in 2025. Research and development expenses were $7.3 million and general and administrative expenses were $4.1 million for the quarter.
aTyr Pharma director Timothy Coughlin received a compensatory stock option grant, giving him the right to acquire 50,000 shares of common stock. The option has an exercise price of $0.95 per share and expires on May 11, 2036.
According to the company’s non-employee director compensation policy, the option vests in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Coughlin continues to serve on the board. After this grant, he holds stock options covering 50,000 shares directly.
aTYR Pharma director Eric Benevich received a new stock option grant. On May 11, 2026, he was awarded options to buy 50,000 shares of aTYR Pharma common stock at an exercise price of $0.95 per share. These options were granted under the company’s non-employee director compensation policy.
The option vests in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, provided he continues serving on the Board of Directors. Following this grant, he holds 50,000 stock options directly.
aTyr Pharma director Jane A. Gross received a grant of stock options covering 50,000 shares of Common Stock. The options have an exercise price of $0.95 per share and were awarded at no upfront cost as a compensation grant.
The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Gross continues to serve on the Board. After this grant, she holds 50,000 stock options directly according to the filing.
aTYR PHARMA INC director Svetlana Lucas received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and expire on May 11, 2036.
The grant was made under the company’s non-employee director compensation policy. The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. This is a compensation-related award rather than an open-market transaction.
aTYR Pharma director Sara Zaknoen received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and were awarded with no purchase price at grant. They vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. After this award, she holds options for 50,000 shares directly.
aTYR Pharma reported that director Paul Schimmel received a grant of stock options as part of the company’s non-employee director compensation policy. The award covers 50,000 options to buy common stock at an exercise price of $0.95 per share, expiring on May 11, 2036.
The option vests in full on the earlier of May 11, 2027 or the company’s 2027 annual stockholders’ meeting, conditioned on his continued board service. Following this grant, Schimmel holds 50,000 stock options directly, and the filing does not show additional derivative holdings.
aTyr Pharma reported preliminary cash, cash equivalents, restricted cash and available-for-sale investments of $68.3 million as of March 31, 2026, and outlined a new pivotal plan for its lead drug efzofitimod in pulmonary sarcoidosis.
Following a Type C meeting with the FDA, the company plans a new global Phase 3 trial in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease, using change in forced vital capacity (FVC) at week 48 as the primary endpoint and the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint.
The 54-week study is expected to enroll about 372 patients on stable low-dose steroids and/or immunosuppressants, with efzofitimod 5.0 mg/kg or placebo given intravenously every three weeks for 17 doses. aTyr intends to file an IND for this C-006 study in June 2026, incorporating enhanced safety monitoring and risk mitigation measures.